Biopharma JV Aims to Double Exports with Expansion Plan

A leading biopharmaceutical joint venture (JV), BF Biosciences (BFBIO), has set its sights on doubling its exports through a phased expansion plan. This follows the successful establishment of a state-of-the-art European-standard manufacturing plant, designed in accordance with international regulatory guidelines.

Speaking to Dawn, BFBIO Chief Operating Officer Muhammad Farhan shared that the company is poised to significantly increase its exports, starting with Rs750 million in the current fiscal year. This figure is expected to double to Rs1.5 billion by the following year. The initial export focus will be on less regulated markets in Central Asia, Africa, and Central America.

“Having completed our plant expansion, we are now preparing to scale up our exports,” Farhan said. He explained that after obtaining key export certifications, the company plans to enter more regulated markets, such as Indonesia, Belarus, and Ukraine. Currently, BFBIO exports its medicines to countries including Sri Lanka, Myanmar, Uganda, Kenya, and the Philippines.

BF Biosciences, a joint venture between Ferozsons Laboratories Ltd and Argentina’s Bagó Group, is also recognized as the only Pakistani company licensed by Gilead Sciences to manufacture and export Remdesivir to various countries across three continents.

Farhan noted that the company’s long-term goal is to achieve US Food and Drug Administration (FDA) certification. “If we secure FDA approval, we will be the first Pakistani company to achieve this milestone,” he said, acknowledging that India already has five companies with FDA certification.

BiopharmaExports #BFBIOServices #PakistanPharma #GlobalPharmaMarkets #RemdesivirManufacture #PharmaceuticalExpansion #USFDACertification #FerozsonsLaboratories #BagoGroup